BioCentury | Mar 26, 2012
Company News

Neurologix neurology news

...using an adeno-associated viral (AAV) vector, is in Phase II testing for Parkinson's disease (PD). Neurologix Inc....
BioCentury | Feb 13, 2012
Company News

Auxilium management update

...as EVP, chief administrative officer and general counsel, formerly president and chief administrative officer of Neurologix Inc. WIR...
BioCentury | Dec 12, 2011
Company News

Auxilium management update

...Genitourinary Hired: Adrian Adams as president, CEO and a director, formerly CEO and chairman of Neurologix Inc....
BioCentury | Dec 9, 2011
Company News

Adams replaces Anido as Auxilium CEO

...director. He replaces Armando Anido, who resigned. Adams is the former CEO and chairman of Neurologix Inc....
BioCentury | Oct 3, 2011
Finance

Value verification

...Inc. (NASDAQ:NSPH) Verigene Gram-Positive Blood Culture (BC-GP) assay Detect Gram-positive bacterial infections Submit 501(k) 4Q11 Neurologix Inc....
BioCentury | Sep 26, 2011
Company News

Neurologix management update

Neurologix Inc. (OTCBB:NRGX), Fort Lee, N.J. Business: Neurology, Gene/Cell therapy Departed: Clark Johnson as vice chairman, president and CEO, while remaining a director Hired: Adrian Adams as CEO and chairman, formerly president and CEO of...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...Inc. (NYSE:CAH) Lymphoseek tilmanocept Identify lymph nodes draining from a primary tumor Submit NDA 3Q11 Neurologix Inc....
BioCentury | Jun 27, 2011
Clinical News

AAV-GAD: Additional Phase II data

..."on" time for patients who received a sham infusion of saline at any time point. Neurologix...
...vs. a sham infusion of saline (see BioCentury, June 28, 2010 & March 21, 2011). Neurologix...
...it plans to submit an SPA to FDA for a Phase III trial this year. Neurologix Inc....
BioCentury | Mar 21, 2011
Product Development

Location, location

...from the first successful Phase II trial of a gene therapy candidate for Parkinson's disease, Neurologix Inc....
...location within the brain where the therapy is infused. In its initial readout last June, Neurologix...
...during a surgical procedure where the patient remains awake. According to scientific co-founder Michael Kaplitt, Neurologix...
BioCentury | Mar 21, 2011
Finance

Highlights of weekly biotech stock moves

...myelofibrosis (PPV-MF/PET-MF). Incyte plans to submit an NDA to FDA next quarter (see B16) . Neurologix Inc....
Items per page:
1 - 10 of 59
BioCentury | Mar 26, 2012
Company News

Neurologix neurology news

...using an adeno-associated viral (AAV) vector, is in Phase II testing for Parkinson's disease (PD). Neurologix Inc....
BioCentury | Feb 13, 2012
Company News

Auxilium management update

...as EVP, chief administrative officer and general counsel, formerly president and chief administrative officer of Neurologix Inc. WIR...
BioCentury | Dec 12, 2011
Company News

Auxilium management update

...Genitourinary Hired: Adrian Adams as president, CEO and a director, formerly CEO and chairman of Neurologix Inc....
BioCentury | Dec 9, 2011
Company News

Adams replaces Anido as Auxilium CEO

...director. He replaces Armando Anido, who resigned. Adams is the former CEO and chairman of Neurologix Inc....
BioCentury | Oct 3, 2011
Finance

Value verification

...Inc. (NASDAQ:NSPH) Verigene Gram-Positive Blood Culture (BC-GP) assay Detect Gram-positive bacterial infections Submit 501(k) 4Q11 Neurologix Inc....
BioCentury | Sep 26, 2011
Company News

Neurologix management update

Neurologix Inc. (OTCBB:NRGX), Fort Lee, N.J. Business: Neurology, Gene/Cell therapy Departed: Clark Johnson as vice chairman, president and CEO, while remaining a director Hired: Adrian Adams as CEO and chairman, formerly president and CEO of...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...Inc. (NYSE:CAH) Lymphoseek tilmanocept Identify lymph nodes draining from a primary tumor Submit NDA 3Q11 Neurologix Inc....
BioCentury | Jun 27, 2011
Clinical News

AAV-GAD: Additional Phase II data

..."on" time for patients who received a sham infusion of saline at any time point. Neurologix...
...vs. a sham infusion of saline (see BioCentury, June 28, 2010 & March 21, 2011). Neurologix...
...it plans to submit an SPA to FDA for a Phase III trial this year. Neurologix Inc....
BioCentury | Mar 21, 2011
Product Development

Location, location

...from the first successful Phase II trial of a gene therapy candidate for Parkinson's disease, Neurologix Inc....
...location within the brain where the therapy is infused. In its initial readout last June, Neurologix...
...during a surgical procedure where the patient remains awake. According to scientific co-founder Michael Kaplitt, Neurologix...
BioCentury | Mar 21, 2011
Finance

Highlights of weekly biotech stock moves

...myelofibrosis (PPV-MF/PET-MF). Incyte plans to submit an NDA to FDA next quarter (see B16) . Neurologix Inc....
Items per page:
1 - 10 of 59